Roche Buys BioImagene, Inc. For $100 Mln, Boosts Diagnostics

ZURICH, Aug 23 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX) is buying U.S-based BioImagene for some $100 million, making another bolt-on acquisition to cement its dominant position in tissue-based cancer diagnostics.